Tempest Therapeutics (TPST) Proxy filing summary

Executive summary

• A special meeting of stockholders was convened to vote on amending the Restated Certificate of Incorporation to replace supermajority voting requirements and allow stockholder action by written consent.

• 67.7% of outstanding shares were represented, constituting a quorum, but not enough votes were received to approve the proposal.

• The meeting was adjourned and will reconvene on August 17, 2026, to allow more time for voting and broader participation.

Voting matters and shareholder proposals

• The main proposal seeks to amend the certificate to eliminate specified supermajority voting requirements and permit stockholder action by written consent.

• Approval requires at least 75% of eligible votes.

• No changes have been made to the proposal; proxies already submitted remain valid unless revoked.

Board of directors and corporate governance

• Directors and executive officers are participating in the proxy solicitation process.

• Information about directors, officers, and their stock ownership is available in recent SEC filings.